TScan Therapeutics Advances Cancer Research with New Screening Study

Tscan Therapeutics, Inc. ((TCRX)) announced an update on their ongoing clinical study.

Study Overview: TScan Therapeutics, Inc. is conducting a screening study titled Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumors. The study aims to collect samples for HLA genotyping, HLA Loss of Heterozygosity (LOH) assessment, and Tumor-associated Antigens (TAA) testing in patients with various metastatic solid tumors. The significance lies in determining eligibility for potential enrollment in further TScan clinical studies.

Intervention/Treatment: The intervention involves a diagnostic test named Tumor and HLA Profiling. This test is designed to perform HLA genotyping and tumor tissue profiling to identify tumor-associated antigens and assess HLA LOH, which are crucial for determining patient eligibility for future therapies.

Study Design: This is an observational study with a case-only model and a prospective time perspective. The primary purpose is diagnostic, focusing on collecting samples with DNA for tumor profiling, without any allocation or masking involved.

Study Timeline: The study began on March 31, 2023, and the latest update was submitted on June 20, 2025. These dates are important as they reflect the study’s progress and ongoing recruitment status, which is crucial for stakeholders tracking the study’s development.

Market Implications: This study update could positively influence TScan Therapeutics’ stock performance and investor sentiment, as it demonstrates ongoing research and development efforts in the competitive field of cancer therapeutics. The study’s focus on multiple solid tumors positions TScan favorably against competitors, potentially enhancing its market position.

The study is currently recruiting, with further details available on the ClinicalTrials portal.